Company intelligence / Profile preview

PowerVision

Belmont, California, United Statespowervision.com ↗

Ownership: Private
Development stage: Phase 2

Overview

PowerVision developed a novel fluid-based accommodating intraocular lens designed to restore the eye’s natural ability to focus at multiple distances. Early clinical trials demonstrated restoration of accommodative functionality in cataract patients. The product was not yet commercially available or approved at the time of acquisition by Alcon in 2019[2][5].

Therapeutic areas: Ophthalmology
Modalities: Device (specifically, implantable intraocular lens)
Industry: Implantable Medical Devices

Drug pipeline

1 asset

FluidVision

Phase 2

Indications: Cataracts, Presbyopia

Beyond the preview

Go deeper on PowerVision.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PowerVision.

Explore the full profile